<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920747</url>
  </required_header>
  <id_info>
    <org_study_id>2021/622</org_study_id>
    <nct_id>NCT04920747</nct_id>
  </id_info>
  <brief_title>Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients</brief_title>
  <acronym>TandHER</acronym>
  <official_title>Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this retrospective study is to evaluate the efficacy and the safety of&#xD;
      trastuzumab + chemotherapies with or without taxanes among HER2-positive advanced&#xD;
      gastroesophageal adenocarcinoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have reported a beneficial role of trastuzumab combined to platin-5-FU based&#xD;
      chemotherapy in first-line advanced HER2 positive gastroesophageal adenocarcinoma. However,&#xD;
      the effect of taxanes combined with platin-5FU + trastuzumab (TPFT) is understudied.&#xD;
&#xD;
      In this context, the aim of this study is to evaluate the efficacy and the safety of&#xD;
      trastuzumab + chemotherapies with or without taxanes among HER2-positive advanced&#xD;
      gastroesophageal adenocarcinoma patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Actual">May 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 12 years</time_frame>
    <description>PFS will be defined as the time interval between the date of randomization and the date of first progression (local, regional, metastatic, second cancer) or death regardless of the cause. Patients alive without progression will be censored at the time of the latest news</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 12 years</time_frame>
    <description>OS will be calculated between the date of randomization and the date of death from any cause. . Alive patients or lost to follow-up at the time of the analysis will be censored at the date of last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 12 years</time_frame>
    <description>Evaluated by RECIST criteria version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>secondary resectability of primary tumor or metastases in patients with DCR</measure>
    <time_frame>up to 12 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>up to 12 years</time_frame>
    <description>graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] criteria v4.03</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">65</enrollment>
  <condition>HER2-positive Gastric Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Docetaxel</condition>
  <condition>Trastuzumab</condition>
  <arm_group>
    <arm_group_label>S group</arm_group_label>
    <description>platin-5FU + trastuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T group</arm_group_label>
    <description>taxanes + platin-5FU + trastuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxane</intervention_name>
    <description>docetaxel or paclitaxel</description>
    <arm_group_label>T group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated between January 2009 and Mars 2021 were included, in 7 centers in&#xD;
        Franche-Comte region in France.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed non-resectable locally advanced, recurrent, or metastatic&#xD;
             adenocarcinoma of the stomach or gastro-esophageal junction;&#xD;
&#xD;
          -  tumor samples scored as 3+ on immunohistochemistry or FISH (Fluorescence in situ&#xD;
             Hybridization) positive (HER2:CEP17 ratio ≥2);&#xD;
&#xD;
          -  measurable disease;&#xD;
&#xD;
          -  treated by trastuzumab, platin (cisplatine or oxaliplatine), fluoropyrimidine (5-FU or&#xD;
             capecitabine) +/- taxanes (docetaxel or paclitaxel),&#xD;
&#xD;
          -  as first-line therapy for advanced gastric cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous chemotherapy by taxane for metastatic disease,&#xD;
&#xD;
          -  previous anti-HER2 therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Besancon</name>
      <address>
        <city>Besançon</city>
        <state>Franche-Comté</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>docetaxel</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>Advanced HER2 Positive Gastroesophageal Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Taxane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

